AVTE实时信号 | 通过Getagraph.com最大化利润

购买 115501 min ago

@ $19.23

发出时间: 13 Feb 2024 @ 22:31

回报率: 4.58%

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:27):

Stats
今日成交量	80 378.00
平均成交量	143 706
市值	577.91M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-0.740 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.01
ATR14	$0.0610 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Dake Benjamin T	Sell	6 853	Stock Option (Right to Buy)
2024-04-17	Dake Benjamin T	Buy	6 853	Common Stock
2024-04-17	Dake Benjamin T	Sell	6 447	Common Stock
2024-04-17	Dake Benjamin T	Sell	338	Common Stock
2024-04-17	Dake Benjamin T	Sell	68	Common Stock

INSIDER POWER
7.22
Last 100 transactions
Buy: 446 022 \| Sell: 367 692

音量相关性

長: 0.29 (neutral)

短: 0.58 (weak)

Signal:(44.977) Neutral

Aerovate Therapeutics, 相关性

10 最正相关
GRIN	0.929
SILK	0.922
DYNT	0.915
EDSA	0.912
NUWE	0.908
ANAB	0.908
UG	0.904
AKU	0.904
ATRA	0.899
FYBR	0.899

10 最负相关
DAKT	-0.917
PESI	-0.908
DUOL	-0.907
BCOR	-0.899
DBVT	-0.896
FEXD	-0.895
BNIX	-0.894
LMB	-0.891
RCII	-0.89
CRWD	-0.888

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aerovate Therapeutics, 相关性 - 货币/商品

0.55
( weak )

0.26
( neutral )

0.00
( neutral )

0.23
( neutral )

-0.40
( neutral )

-0.12
( neutral )

Aerovate Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-96 000.00 (0.00 %)
EPS:	$-2.87

FY	2023
营收:	$0
毛利润:	$-96 000.00 (0.00 %)
EPS:	$-2.87

FY	2022
营收:	$0
毛利润:	$-68 000.00 (0.00 %)
EPS:	$-2.10

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-9.67

Financial Reports:

No articles found.

Aerovate Therapeutics,

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.